The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes [1] [2]
Residual unreacted HSA was removed by three consecutive pulses of 9 s with 25 mM NaOH (3 l), resulting in a surface of 14,360 RFU
FIGURE 8 3.4 Evaluation of basic pharmacological profile of SR18 Taking cue from the comparative MD simulation data, SR18 was custom-synthesized and purified to homogeneity, with a purity level of 95%, as evident from the analytical HPLC profile
Additional considerations include: Gastrointestinal effects : Wegovy commonly causes nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation